Business
Bavarian Nordic Publishes Annual Report 2025
COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today published its annual report for 2025. The consolidated, audited results were in line with the preliminary results announced on February 12, 2026. The report is attached and available on www.bavarian-nordic.com. “Our 2025 annual report confirms the strong preliminary results reported last month and we are well underway in the execution of our plans for 2026 to deliver continued growth in our Travel Health business. Organi
About this update from Bavarian Nordic A/s
[{"type":"image","alt":"Bavarian Nordic A/S","displaySize":"","headline":null,"caption":"Bavarian Nordic A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":224,"height":118,"url":"https://media.zenfs.com/en/globenewswire.com/8b66f55ff95ddf48491741d682cbdfa0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/X7d037B4FI93H1mEWMcPsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8b66f55ff95ddf48491741d682cbdfa0","width":224,"height":118}},"lazy":false},{"type":"text","content":"COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today published its annual report for 2025. The consolidated, audited results were in line with the preliminary results announced on February 12, 2026. The report is attached and available on www.bavarian-nordic.com.","length":286,"tagName":"p"},{"type":"text","content":"“Our 2025 annual report confirms the strong preliminary results reported last month and we are well underway in the execution of our plans for 2026 to deliver continued growth in our Travel Health business. Organic growth in our core products, rabies and TBE, remains strong, and is further stimulated by the continued global launch of our chikungunya vaccine,” said Paul Chaplin, President and CEO of Bavarian Nordic. “2026 marks the first year where revenues from Travel Health will surpass our Public Preparedness business, which is expected to normalize after several outbreak years. This is a strong validation of the strategic transformation of Bavarian Nordic – a direction, which we remain dedicated to pursuing. 2026 also marks a change in leadership as I will step down as the CEO later in 2026 as announced earlier this month. It has been a privilege, and I am proud of the achievements we have made together, which have created a strong foundation for the future of the company.”","length":991,"tagName":"p"},{"type":"text","content":"Significant events after the balance sheet date","length":47,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In January, Bavarian Nordic launched the first tranche of a planned share buy-back program for up to DKK 500 million during 2026. The first tranche comprised buy-back of shares for up to DKK 150 million and was completed in February. The shares will be held as treasury stock for the purpose of adjusting the capital ...